Palisade Bio has begun the multiple ascending dose (MAD) cohorts of its ongoing Phase Ia/b trial of PALI-2108 for ulcerative ...

The company said that all of its CONNEX trials failed to meet expectations showing no impact on patients living with ...

Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

The announcement comes after the company secured an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA) for the MagicTouch PTA. Credit: Shutterstock / Iryna ...

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

The Paul-Ehrlich-Institute (PEI) in Germany has granted approval to continue subject enrolment in cohort 5 of Oncolytics' GOBLET trial ...

Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.

Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...

Once Humira biosimilars entered the US markets in 2023, drug revenues declined by 32% for AbbVie. Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi ...